Comparison · Updated
CJC-1295 (with DAC) VS CJC-1295 No DAC
Short answer
CJC-1295 (with DAC) has stronger published evidence than CJC-1295 No DAC: tier A (Controlled human trials) vs tier C (Animal data).
Neither CJC-1295 (with DAC) nor CJC-1295 No DAC is FDA-approved.
Both are prohibited in sport by WADA under section S2.
01
Side by side
| Field | CJC-1295 (with DAC) | CJC-1295 No DAC |
|---|---|---|
| Evidence tier | A Tier A · Controlled human trials | C Tier C · Animal data |
| Tier rationale | Randomized, placebo-controlled dose studies in healthy adults were published (2006); development was discontinued and it is not approved. | Published data are mostly preclinical; no completed human trials of this compound were found. |
| FDA status | Not approved | Not approved |
| Other approvals | None listed | None listed |
| WADA | Prohibited · S2Peptide hormones, growth factors, related substances and mimetics | Prohibited · S2Peptide hormones, growth factors, related substances and mimetics |
| Family | GH & Growth | GH & Growth |
| Residues | Not on file | Not on file |
| Molecular weight | Not on file | Not on file |
| Formula | Not on file | Not on file |
| Discovered | Not on file | Not on file |
| Routes studied | Subcutaneous, Intramuscular | Subcutaneous, Intramuscular |
| Mechanism | CJC-1295 DAC is a synthetic GHRH analog with four amino acid substitutions for enzymatic stability plus a drug affinity complex (DAC) that binds albumin, extending the half-life to 6-8 days. It binds the GHRH receptor on pituitary somatotrophs, activating cAMP-PKA signaling to promote sustained GH secretion. | CJC-1295 no DAC (modified GRF 1-29) binds the GHRH receptor on pituitary somatotrophs, stimulating GH release via adenylyl cyclase/cAMP signaling. Without the DAC moiety it has a half-life of approximately 30 minutes, producing a sharp GH pulse that closely mimics the natural pulsatile secretion pattern. |
| Safety notes | Phase II trials showed generally well-tolerated profile. | Well-tolerated in clinical settings. |
| Cited studies | 1 study | 1 study |
02
Questions
- Which has stronger evidence, CJC-1295 (with DAC) or CJC-1295 No DAC?
- CJC-1295 (with DAC) has stronger published evidence than CJC-1295 No DAC: tier A (Controlled human trials) vs tier C (Animal data). CJC-1295 (with DAC): Randomized, placebo-controlled dose studies in healthy adults were published (2006); development was discontinued and it is not approved. CJC-1295 No DAC: Published data are mostly preclinical; no completed human trials of this compound were found. Tiers rate the strength of published evidence, not effectiveness.
- Is CJC-1295 (with DAC) FDA-approved?
- CJC-1295 (with DAC) is not FDA-approved.
- Is CJC-1295 No DAC FDA-approved?
- CJC-1295 No DAC is not FDA-approved.
- Are CJC-1295 (with DAC) and CJC-1295 No DAC banned in sport?
- Both are prohibited in sport by WADA under section S2.
- How do CJC-1295 (with DAC) and CJC-1295 No DAC work?
- CJC-1295 DAC is a synthetic GHRH analog with four amino acid substitutions for enzymatic stability plus a drug affinity complex (DAC) that binds albumin, extending the half-life to 6-8 days. CJC-1295 no DAC (modified GRF 1-29) binds the GHRH receptor on pituitary somatotrophs, stimulating GH release via adenylyl cyclase/cAMP signaling.